nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

02.05.2018 | Original Article

⁶⁸Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients

verfasst von: Chen Liu, Teli Liu, Ning Zhang, Yiqiang Liu, Nan Li, Peng Du, Yong Yang, Ming Liu, Kan Gong, Xing Yang, Hua Zhu, Kun Yan, Zhi Yang

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to investigate the performance of ⁶⁸Ga-PSMA-617 PET/CT in predicting risk stratification and metastatic risk of prostate cancer.

Methods

Fifty newly diagnosed patients with prostate cancer as confirmed by needle biopsy were continuously included, 40 in a train set and ten in a test set. ⁶⁸Ga-PSMA-617 PET/CT and clinical data of all patients were retrospectively analyzed. Semi-quantitative analysis of PET images provided maximum standardized uptake (SUVmax) of primary prostate cancer and volumetric parameters including intraprostatic PSMA-derived tumor volume (iPSMA-TV) and intraprostatic total lesion PSMA (iTL-PSMA). According to prostate cancer risk stratification criteria of the NCCN Guideline, all patients were simplified into a low-intermediate risk group or a high-risk group. The semi-quantitative parameters of ⁶⁸Ga-PSMA-617 PET/CT were used to establish a univariate logistic regression model for high-risk prostate cancer and its metastatic risk, and to evaluate the diagnostic efficacy of the predictive model.

Results

In the train set, 30/40 (75%) patients had high-risk prostate cancer and 10/40 (25%) patients had low-to-moderate-risk prostate cancer; in the test set, 8/10 (80%) patients had high-risk prostate cancer while 2/10 (20%) had low-intermediate risk prostate cancer. The univariate logistic regression model established with SUVmax, iPSMA-TV and iTL-PSMA could all effectively predict high-risk prostate cancer; the AUC of ROC were 0.843, 0.802 and 0.900, respectively. Based on the test set, the sensitivity and specificity of each model were 87.5% and 50% for SUVmax, 62.5% and 100% for iPSMA-TV, and 87.5% and 100% for iTL-PSMA, respectively. The iPSMA-TV and iTL-PSMA-based predictive model could predict the metastatic risk of prostate cancer, the AUC of ROC was 0.863 and 0.848, respectively, but the SUVmax-based prediction model could not predict metastatic risk.

Conclusions

Semi-quantitative analysis indexes of ⁶⁸Ga-PSMA-617 PET/CT imaging can be used as “imaging biomarkers” to predict risk stratification and metastatic risk of prostate cancer.

Nur mit Berechtigung zugänglich

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–7. https://doi.org/10.1200/JCO.2014.55.1192.CrossRefPubMed

Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23. https://doi.org/10.1200/JCO.2009.26.0133.CrossRefPubMedPubMedCentral

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMed

European Association of Urology Guidelines on prostate cancer. uroweb.org [online]. http://uroweb.org/guideline/prostate-cancer. Accessed 24 April 2018

National Comprehensive Cancer Network. (NCCN) Clinical practice guidelines in oncology. Prostate Cancer, Version 2. 2017. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

Marchal C, Redondo M, Padilla M, Caballero J, Rodrigo I, Garcia J, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol. 2004;19(3):715–8. https://doi.org/10.14670/HH-19.715.PubMedCrossRef

Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71(3):281–8. https://doi.org/10.1002/pros.21241.CrossRefPubMed

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62.PubMed

10.

Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.CrossRefPubMed

11.

Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–34.CrossRefPubMed

12.

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. https://doi.org/10.1007/s00259-014-2949-6.CrossRefPubMed

13.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68. https://doi.org/10.1007/s00259-017-3711-7.CrossRefPubMedPubMedCentral

14.

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94. https://doi.org/10.1007/s00259-015-3078-6.CrossRefPubMed

15.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70(5):829–36. https://doi.org/10.1016/j.eururo.2015.12.053.CrossRefPubMed

16.

Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43(3):397–403. https://doi.org/10.1007/s00259-015-3240-1.CrossRefPubMed

17.

Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941–9. https://doi.org/10.1007/s00259-017-3631-6.CrossRefPubMed

18.

Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer. Clin Nucl Med. 2016;41(11):e473–e9. https://doi.org/10.1097/RLU.0000000000001349.CrossRefPubMed

19.

Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.117.193581.

20.

Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, et al. Correlation of intraprostatic tumor extent with (6)(8)Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57(4):563–7. https://doi.org/10.2967/jnumed.115.169243.CrossRefPubMed

21.

Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, et al. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017;7(1):228–37. https://doi.org/10.7150/thno.16638.CrossRefPubMedPubMedCentral

22.

Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57(11):1720–5. https://doi.org/10.2967/jnumed.116.172627.CrossRefPubMed

23.

Zang S, Shao G, Cui C, Li TN, Huang Y, Yao X, et al. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget. 2017;8(7):12247–58. https://doi.org/10.18632/oncotarget.14691.PubMedPubMedCentralCrossRef

24.

Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696–701. https://doi.org/10.1016/j.humpath.2006.11.012.CrossRefPubMed

25.

Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, et al. (68)Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med. 2017;58(12):1943–8. https://doi.org/10.2967/jnumed.117.190314.CrossRefPubMed

26.

Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim DJ, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015;56(1):45–9. https://doi.org/10.2967/jnumed.114.147561.CrossRefPubMed

27.

Park SY, Cho A, Bae MK, Lee CY, Kim DJ, Chung KY. Value of 18F-FDG PET/CT for predicting the World Health Organization malignant grade of Thymic epithelial tumors: focused in volume-dependent parameters. Clin Nucl Med. 2016;41(1):15–20. https://doi.org/10.1097/RLU.0000000000001032.CrossRefPubMed

28.

Bjurlin MA, Rosenkrantz AB, Beltran LS, Raad RA, Taneja SS. Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol. 2015;12(11):617–28. https://doi.org/10.1038/nrurol.2015.242.CrossRefPubMed

29.

Tokuda Y, Carlino LJ, Gopalan A, Tickoo SK, Kaag MG, Guillonneau B, et al. Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol. 2010;34(12):1862–7. https://doi.org/10.1097/PAS.0b013e3181fc679e.CrossRefPubMedPubMedCentral

30.

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57(Suppl 3):79S–89S. https://doi.org/10.2967/jnumed.115.170720.CrossRefPubMed

31.

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. https://doi.org/10.1007/s00259-012-2298-2.CrossRefPubMed

32.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70(5):829–36. https://doi.org/10.1016/j.eururo.2015.12.053.CrossRefPubMed

33.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43. https://doi.org/10.1016/j.juro.2015.12.025.CrossRefPubMed

34.

Sachpekidis C, Baumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, et al. (68)Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-3936-0.

35.

Janssen JC, Meissner S, Woythal N, Prasad V, Brenner W, Diederichs G, et al. Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: additional value of morphologic information from low dose CT. Eur Radiol. 2018;28(2):610–9. https://doi.org/10.1007/s00330-017-4994-6.CrossRefPubMed

Titel: 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients
verfasst von: Chen Liu
Teli Liu
Ning Zhang
Yiqiang Liu
Nan Li
Peng Du
Yong Yang
Ming Liu
Kan Gong
Xing Yang
Hua Zhu
Kun Yan
Zhi Yang
Publikationsdatum: 02.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4037-9

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT

Gamma probe and ultrasound-guided fine needle aspiration cytology of the sentinel node (GULF) trial

Ferdinando Calabria and Orazio Schillaci (Eds). Radiopharmaceuticals. Metabolic Pathways for PET/CT and PET/MRI Imaging

A rare presentation of skull-base osteomyelitis with neurovascular sheath extension following external otitis resolved by PET/MRI

Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy

Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer